- Home
- KRUS vs RLAY Comparison
KRUS vs RLAY Comparison
Compare KRUS & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRUS | RLAY |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.3M | 1.4B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KRUS | RLAY |
|---|---|---|
| Price | $55.46 | $8.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $84.29 | $16.00 |
| AVG Volume (30 Days) | 318.4K | ★ 2.3M |
| Earning Date | 01-07-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $282,763,000.00 | $8,355,000.00 |
| Revenue This Year | $19.06 | $20.47 |
| Revenue Next Year | $20.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 18.88 | N/A |
| 52 Week Low | $40.03 | $1.78 |
| 52 Week High | $106.60 | $9.04 |
Technical Indicators
Market Signals| Indicator | KRUS | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 57.46 | 63.83 |
| Support Level | $53.00 | $8.13 |
| Resistance Level | $55.50 | $8.81 |
| Average True Range (ATR) | 2.24 | 0.51 |
| MACD | 0.52 | 0.02 |
| Stochastic Oscillator | 81.21 | 75.93 |
Price Performance
Historical ComparisonAbout KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).